These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 18184535)
1. Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man. Tuerck D; Wang Y; Maboudian M; Wang Y; Sedek G; Pommier F; Appel-Dingemanse S Int J Clin Pharmacol Ther; 2007 Dec; 45(12):662-8. PubMed ID: 18184535 [TBL] [Abstract][Full Text] [Related]
2. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers. Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029 [TBL] [Abstract][Full Text] [Related]
4. A Comparison of the Pharmacokinetics of Methylphenidate Extended-Release Orally Disintegrating Tablets With a Reference Extended-Release Formulation of Methylphenidate in Healthy Adults. Childress A; Stark JG; McMahen R; Engelking D; Sikes C Clin Pharmacol Drug Dev; 2018 Feb; 7(2):151-159. PubMed ID: 28544581 [TBL] [Abstract][Full Text] [Related]
5. Single-dose Pharmacokinetic Properties and Relative Bioavailability of a Novel Methylphenidate Extended-release Chewable Tablet Compared With Immediate-release Methylphenidate Chewable Tablet. Abbas R; Palumbo D; Walters F; Belden H; Berry SA Clin Ther; 2016 May; 38(5):1151-7. PubMed ID: 27021606 [TBL] [Abstract][Full Text] [Related]
6. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ; Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578 [TBL] [Abstract][Full Text] [Related]
7. Single-dose pharmacokinetics of methylphenidate extended-release multiple layer beads administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (Ritalin(®)) in healthy adult volunteers. Adjei A; Teuscher NS; Kupper RJ; Chang WW; Greenhill L; Newcorn JH; Connor DF; Wigal S J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):570-8. PubMed ID: 25514542 [TBL] [Abstract][Full Text] [Related]
9. Fed and Fasted Administration of a Novel Extended-Release Methylphenidate Orally Disintegrating Tablet Formulation for the Treatment of ADHD. Weisler RH; Stark JG; Sikes C Clin Pharmacol Drug Dev; 2018 Feb; 7(2):160-167. PubMed ID: 28544344 [TBL] [Abstract][Full Text] [Related]
10. A Pharmacokinetic Study of Methylphenidate Hydrochloride Multilayer Extended-Release Capsules (Aptensio XR Adjei AL; Chaudhary I; Kollins SH; Padilla A Paediatr Drugs; 2020 Oct; 22(5):561-570. PubMed ID: 32776159 [TBL] [Abstract][Full Text] [Related]
11. A single-dose, two-way crossover, bioequivalence study of dexmethylphenidate HCl with and without food in healthy subjects. Teo SK; Scheffler MR; Wu A; Stirling DI; Thomas SD; Stypinski D; Khetani VD J Clin Pharmacol; 2004 Feb; 44(2):173-8. PubMed ID: 14747426 [TBL] [Abstract][Full Text] [Related]
12. Relative Bioavailability of Methylphenidate Extended-release Chewable Tablets Chewed Versus Swallowed Whole. Abbas R; Childress AC; Nagraj P; Rolke R; Berry SA; Palumbo DR Clin Ther; 2018 May; 40(5):733-740. PubMed ID: 29703430 [TBL] [Abstract][Full Text] [Related]
13. A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Childress A; Newcorn J; Stark JG; McMahen R; Tengler M; Sikes C J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):505-12. PubMed ID: 27228207 [TBL] [Abstract][Full Text] [Related]
14. The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. Childress AC; Berry SA Postgrad Med; 2010 Sep; 122(5):35-41. PubMed ID: 20861586 [TBL] [Abstract][Full Text] [Related]
15. Does chirality matter? pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder. Quinn D J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S62-6. PubMed ID: 18480679 [TBL] [Abstract][Full Text] [Related]
16. Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder. Moen MD; Keam SJ CNS Drugs; 2009 Dec; 23(12):1057-83. PubMed ID: 19958043 [TBL] [Abstract][Full Text] [Related]
18. Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder. Childress A; Mehrotra S; Gobburu J; McLean A; DeSousa NJ; Incledon B J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):10-18. PubMed ID: 29039979 [TBL] [Abstract][Full Text] [Related]
19. Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations. Patrick KS; Radke JL; Raymond JR; Koller L; Nguyen LV; Rodriguez W; Straughn AB Pharmacotherapy; 2019 Jun; 39(6):677-688. PubMed ID: 30351459 [TBL] [Abstract][Full Text] [Related]
20. Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder. Sugrue D; Bogner R; Ehret MJ Am J Health Syst Pharm; 2014 Jul; 71(14):1163-70. PubMed ID: 24973373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]